TACE for Liver Cancer in Turkey
Transarterial chemoembolisation (TACE) is a minimally invasive, catheter-based procedure that delivers chemotherapy directly to liver tumours while cutting off their blood supply. Turkey's leading interventional oncology teams perform TACE with excellent outcomes at accessible costs.
Hepatocellular carcinoma (HCC) — primary liver cancer — is one of the most prevalent cancers globally, and its management often requires a multidisciplinary approach that goes beyond systemic chemotherapy or surgery. Transarterial chemoembolisation (TACE) has become a cornerstone treatment for intermediate-stage HCC and for patients awaiting liver transplantation. Turkey's internationally accredited hospitals offer TACE performed by experienced interventional radiologists, with comprehensive oncological support, at a cost that makes treatment accessible to international patients from across the Middle East, Africa, and Europe.
What is TACE?
TACE — transarterial chemoembolisation — is a minimally invasive procedure that exploits the fact that liver tumours derive the majority of their blood supply from the hepatic artery, whereas healthy liver tissue is primarily supplied by the portal vein. During TACE, a catheter is threaded through the femoral artery in the groin up to the hepatic artery. Chemotherapy drugs (most commonly doxorubicin, cisplatin, or mitomycin C) are injected directly into the artery feeding the tumour, followed by embolic particles that block blood flow to the tumour. This dual mechanism — high local chemotherapy concentration combined with ischaemia — causes tumour cell death while largely sparing healthy liver tissue. A refinement called drug-eluting bead TACE (DEB-TACE) uses microspheres that both carry and slowly release chemotherapy, reducing systemic exposure further.
How is it Performed?
TACE is performed under local anaesthesia with sedation in an interventional radiology suite. After the femoral artery is accessed, a thin catheter is guided using real-time fluoroscopy and digital subtraction angiography (DSA) through the aorta and into the hepatic arterial tree. Superselective catheterisation — advancing the catheter as close as possible to the tumour-feeding artery — maximises drug delivery to the tumour while reducing damage to healthy liver parenchyma. The chemotherapy-embolic mixture is then injected under fluoroscopic guidance. The procedure typically takes one to two hours. Patients are admitted for one or two nights for monitoring and pain management.
Who is a Candidate?
TACE is recommended for patients with HCC at Barcelona Clinic Liver Cancer (BCLC) intermediate stage (B) — typically those with multinodular tumours not suitable for curative surgery or ablation, but with preserved liver function and no major vascular invasion or distant metastasis. It is also used as a bridge therapy in transplant candidates to prevent tumour progression while awaiting a donor organ, and as a palliative option for selected patients with metastatic tumours to the liver (from colorectal, neuroendocrine, or other primaries). Patients require adequate hepatic reserve, assessed by Child-Pugh score and liver function tests. TACE is generally contraindicated in patients with decompensated cirrhosis (Child-Pugh C), complete portal vein thrombosis, or significantly reduced blood cell counts.
Recovery & Aftercare
Post-TACE syndrome — fever, abdominal pain, nausea, and fatigue — is common and typically lasts three to seven days after the procedure. This is a predictable response to tumour cell death rather than a complication. Patients are managed with analgesics, antiemetics, and supportive care. Most international patients are ready to travel home within three to five days of the procedure. Follow-up contrast-enhanced MRI or CT is performed four to six weeks later to assess tumour response using modified RECIST or mRECIST criteria. Repeat TACE sessions are often planned every six to twelve weeks depending on tumour response.
Why Turkey & Turkare?
Turkey's leading cancer hospitals house dedicated interventional oncology units equipped with state-of-the-art biplane angiography suites that enable superselective catheterisation with high precision. Interventional radiologists performing TACE in Turkey hold extensive experience with hundreds of procedures annually. TACE in Turkey costs $5,000–$12,000 per session all-inclusive, compared to $15,000–$30,000 in Western Europe or the United States. Turkare coordinates your entire treatment episode: pre-procedure imaging review, hospital and physician selection, travel and accommodation logistics, bedside interpretation, and the organisation of follow-up scans with remote reporting. We also facilitate direct communication between your Turkish team and your oncologist at home.
Frequently asked questions
How many TACE sessions are typically needed, and how long must I stay in Turkey?
Most patients require two to four TACE sessions over the course of their treatment, with each session separated by six to twelve weeks to allow for tumour response assessment. Each individual session requires a hospital stay of two to three days (one day for the procedure plus overnight monitoring), plus travel days. In total, most patients plan a trip of five to seven days per session. Turkare helps structure the overall treatment timeline so sessions can be spaced around your commitments at home.
Is TACE painful? What should I expect during and after the procedure?
The procedure itself is performed under sedation and is not painful — patients feel drowsy and relaxed. After TACE, it is normal to experience what is called post-embolisation syndrome: abdominal aching or right-sided pain, low-grade fever, nausea, and fatigue lasting three to seven days. Your medical team manages these symptoms with pain relief and antiemetics. By discharge, most patients feel significantly better. The symptoms, though uncomfortable, are a sign that the treatment is working — the body is responding to the destruction of tumour tissue.
How does TACE compare to systemic chemotherapy or surgery for liver cancer?
Surgical resection remains the gold standard for early-stage HCC in patients with sufficient healthy liver, but only a minority of patients are surgical candidates at diagnosis. Systemic chemotherapy historically showed limited benefit in HCC, though newer agents (sorafenib, lenvatinib) have improved outcomes in advanced disease. TACE occupies the intermediate space: it is more effective than systemic therapy for localised or multi-nodular liver disease and avoids the risks of major surgery. Studies show median overall survival of 20–30 months for intermediate-stage HCC treated with TACE, with some patients achieving tumour downstaging that makes them surgical candidates.
Is my liver function adequate for TACE? What tests are needed?
TACE requires sufficient residual liver function to withstand both the procedure and the inflammatory response that follows. Your suitability is assessed using the Child-Pugh scoring system (based on bilirubin, albumin, INR, ascites, and encephalopathy) and liver function blood tests. Most candidates for TACE are Child-Pugh A or early B. An ECOG performance status of 0–2 is also expected. Turkare's coordinators will request your most recent blood results, liver imaging, and any available liver biopsy reports before your arrival to expedite this assessment.
How is tumour response monitored after TACE, and how will my home doctor be informed?
Tumour response to TACE is assessed using contrast-enhanced MRI or CT performed four to six weeks after each session. Radiologists measure the area of tumour necrosis and any remaining enhancing viable tumour using mRECIST criteria. Before you leave Turkey, your interventional radiologist and oncologist produce a detailed procedure report covering technique, embolic materials used, and immediate imaging findings. This report — along with post-TACE imaging — is shared digitally with your home oncologist. Turkare facilitates telemedicine consultations between your Turkish team and home physician to discuss response assessment and plan subsequent sessions.
Get a written quote for this procedure
One coordinator, one price, start to finish.
